The Cleveland Clinic Foundation

Retension Pharmaceuticals completed a $15 million Series B financing round to advance RTN-001, a novel PDE5 inhibitor designed for uncontrolled and resistant hypertension treatment.

Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.

LifePlus announced clinical validation of LifeLeaf®, the world's first non-invasive wearable for continuous glucose and blood pressure tracking, tested at Mayo Clinic, Cleveland Clinic, and other global centers.

Cerapedics received FDA premarket approval for PearlMatrix P-15 Peptide Enhanced Bone Graft, the first proven bone growth accelerator for lumbar fusion procedures.

The FDA has approved Neuspera Medical's integrated sacral neuromodulation (iSNM) system, the first battery-free device for treating urinary urge incontinence (UUI).

Biologic therapies including dupilumab, benralizumab, and tezepelumab have revolutionized asthma management by enabling biomarker-driven treatment strategies beyond traditional allergen or eosinophil-based models.

ANGLE's Parsortix system has enabled multiple breakthrough studies published in high-impact journals, revealing novel insights into circulating tumor cell biology and cancer metastasis mechanisms.

The phase 3 KEYNOTE-630 trial found that adjuvant pembrolizumab did not significantly improve progression-free survival in patients with high-risk cutaneous squamous cell carcinoma following surgery and radiation.

The phase 3 ATOMIC trial demonstrated that adding atezolizumab to standard chemotherapy reduced the risk of recurrence or death by 50% in patients with stage III dMMR colon cancer.

A comprehensive Norwegian population study of 26,210 pregnancies found no increased risk of neurodevelopmental disorders, including autism and ADHD, in children whose mothers used triptans for migraine treatment during pregnancy.